Angiodynamics To Realize Independence From E-Z-Em Through IPO
This article was originally published in The Gray Sheet
Executive Summary
Angiodynamics asserts that its focus on peripheral vascular disease (PVD) and its broad product line will enable the firm to hold its own against larger competitors once it goes public
You may also be interested in...
Financings In Brief
Cooper Companies: Firm's proposed $1.2 bil. acquisition of Ocular Sciences garners required shareholder approval Nov. 16. However, closure of the transaction, originally expected by November, continues to be delayed as the Federal Trade Commission reviews additional information it requested in September to supplement the two companies' initial Aug. 6 submission of merger-related information (1"The Gray Sheet" Sept. 13, 2004, p. 24). Cooper now predicts the transaction will close during the first half of its fiscal 2005, which began Nov. 1...
Financings In Brief
Cooper Companies: Firm's proposed $1.2 bil. acquisition of Ocular Sciences garners required shareholder approval Nov. 16. However, closure of the transaction, originally expected by November, continues to be delayed as the Federal Trade Commission reviews additional information it requested in September to supplement the two companies' initial Aug. 6 submission of merger-related information (1"The Gray Sheet" Sept. 13, 2004, p. 24). Cooper now predicts the transaction will close during the first half of its fiscal 2005, which began Nov. 1...
Financings In Brief
Microsulis: Firm will use $45 mil. round financing to hire 50 direct sales reps/physician educators to support full launch of Microwave Endometrial Ablation (MEA) system to treat menorrhagia. Approved last September, MEA has been slowly rolled out, awaiting funding for clinical specialists required under FDA clearance (1"The Gray Sheet" Oct. 20, 2003, In Brief). Microsulis currently is evaluating distributors for metropolitan areas. The funds also will go to support separate 510(k) applications for soft tissue ablation and peripheral vascular indications to be submitted by year-end. Existing investors contributed $20 mil. to the round, while the remaining $25 mil. came from venture capital...